MELBOURNE, Australia, May 2 /PRNewswire-FirstCall/ — Australia’s adult stem cell company, Mesoblast Limited (ASX: MSB; US OTC: MBLTY), today announced that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) of its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or ‘off-the-shelf’, adult stem cells for patients with heart attacks..

The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company’s proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement in heart function and reduction in congestive heart failure.

There they go again. Darn it! Why do they insist on doing research using adult stem cells? Don’t they know that embryonic stem cells are more “promising” and “hopeful”? Someone needs to tell them to cut it out before they treat something that we’ve all been promised will be treated with ESCs. Oh, wait, they already do that!

H/T: Wesley Smith

Previous post:
First Human Phase II ASC Therapy Trial in US